/TERN
TERN Stock - Terns Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$39.90+0.20%
+$0.08 (+0.20%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).25
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-12.7%upside
Target: $34.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TERN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$39.50 – $40.30
TARGET (TP)$34.83
STOP LOSS$36.71
RISK/REWARD1:-1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.24
52W High$48.26
52W Low$1.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $1.00M | N/A |
| Gross Profit | N/A | N/A | N/A | $1.00M | N/A |
| Gross Margin | N/A | N/A | N/A | 100.0% | N/A |
| Operating Income | $-101,871,000 | $-102,558,000 | $-62,029,000 | $-49,860,000 | $-37,025,000 |
| Net Income | $-88,853,000 | $-90,210,000 | $-60,345,000 | $-50,158,000 | $-29,352,000 |
| Net Margin | N/A | N/A | N/A | -5015.8% | N/A |
| EPS | $-1.12 | $-1.27 | $-1.67 | $-1.98 | $-1.61 |
Company Overview
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
83%
Hold / Neutral
2
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish2 Neutral/Bearish
Price Targets
$23
Average Target
↓ 42.1% Downside
Now
$6
Low
$23
Average
$82
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 4th 2025 | H.C. Wainwright | Upgrade | Buy | $20 |
| November 3rd 2025 | William Blair | Upgrade | Outperform | - |
| October 15th 2025 | Truist | Initiation | Buy | $20 |
| September 17th 2025 | Barclays | Initiation | Overweight | $15 |
| September 4th 2025 | H.C. Wainwright | Resumed | Neutral | - |
| February 28th 2025 | William Blair | Initiation | Market Perform | - |
| October 31st 2024 | Oppenheimer | Initiation | Outperform | $82 |
| June 22nd 2023 | Mizuho | Initiation | Buy | $16 |
| June 7th 2023 | Jefferies | Initiation | Buy | $18 |
| May 31st 2023 | ROTH MKM | Initiation | Buy | $23 |
| May 8th 2023 | BMO Capital Markets | Initiation | Outperform | $18 |
| February 14th 2023 | JMP Securities | Initiation | Mkt Outperform | $17 |
| February 7th 2023 | UBS | Initiation | Buy | $19 |
| September 12th 2022 | H.C. Wainwright | Initiation | Neutral | $6 |
Earnings History & Surprises
TERNBeat Rate
83%
Last 18 quarters
Avg Surprise
+12.6%
EPS vs Estimate
Beats / Misses
15/2
1 met exactly
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.29vs$-0.29
Q2 24
+16.7%
$-0.30vs$-0.36
Q3 24
+11.4%
$-0.31vs$-0.35
Q4 24
+15.2%
$-0.28vs$-0.33
Q1 25
+20.0%
$-0.24vs$-0.30
Q2 25
+10.3%
$-0.26vs$-0.29
Q3 25
+7.1%
$-0.26vs$-0.28
Q4 25
+10.0%
$-0.27vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.30 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.29 | $-0.26 | +10.3% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.30 | $-0.24 | +20.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.35 | $-0.31 | +11.4% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.36 | $-0.30 | +16.7% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.29 | $-0.29 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.31 | $-0.42 | -35.5% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.32 | $-0.25 | +21.9% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.42 | $-0.29 | +31.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.51 | $-0.44 | +13.7% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.63 | $-0.55 | +12.7% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.67 | $-0.55 | +17.9% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.67 | $-0.56 | +16.4% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.60 | $-0.47 | +21.7% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.81 | $-0.43 | +46.9% | ✓ BEAT |
Latest News
Citizens Maintains Market Outperform on Terns Pharma, Raises Price Target to $57
📈 PositiveBenzinga•Dec 11, 2025, 01:39 PM
Terns Pharmaceuticals shares are trading higher. The company announced the pricing of its $650 million public offering at $40.00 per share.
📈 PositiveBenzinga•Dec 10, 2025, 04:17 PM
Reported Earlier, Terns Pharmaceuticals Prices Upsized $650M Underwritten Public Offering At $40.00 Per Share, Advancing Oncology Pipeline And TERN-701
📈 PositiveBenzinga•Dec 10, 2025, 08:05 AM
Truist Securities Maintains Buy on Terns Pharma, Raises Price Target to $56
📈 PositiveBenzinga•Dec 9, 2025, 05:38 PM
Oppenheimer Maintains Outperform on Terns Pharma, Raises Price Target to $58
📈 PositiveBenzinga•Dec 9, 2025, 05:34 PM
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $54
📈 PositiveBenzinga•Dec 9, 2025, 04:52 PM
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $56
📈 PositiveBenzinga•Dec 9, 2025, 04:46 PM•Also:
Mizuho Maintains Outperform on Terns Pharma, Raises Price Target to $54
📈 PositiveBenzinga•Dec 9, 2025, 01:47 PM
HC Wainwright & Co. Maintains Buy on Terns Pharma, Raises Price Target to $60
📈 PositiveBenzinga•Dec 9, 2025, 11:33 AM
Terns Pharma Plans $400M Stock Offering To Fund Cancer Drug Development
📈 PositiveBenzinga•Dec 9, 2025, 11:20 AM
Trading Halt: Halt status updated at 3:00:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 8, 2025, 08:00 PM
Terns Pharma Presents Updated And Expanded Data From Ongoing CARDINAL Trial Of TERN-701 In Patients With Previously Treated CML At ASH Annual Meeting And Exposition
➖ NeutralBenzinga•Dec 8, 2025, 07:53 PM
Trading Halt: Halted at 2:40:00 p.m. ET - Trading Halt: Halt News Pending
📉 NegativeBenzinga•Dec 8, 2025, 07:40 PM
Citizens Maintains Market Outperform on Terns Pharma, Raises Price Target to $35
📈 PositiveBenzinga•Nov 26, 2025, 11:10 AM
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $36
📈 PositiveBenzinga•Nov 25, 2025, 03:05 PM•Also: ,
Truist Securities Maintains Buy on Terns Pharma, Raises Price Target to $35
📈 PositiveBenzinga•Nov 19, 2025, 05:51 PM•Also:
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $30
📈 PositiveBenzinga•Nov 18, 2025, 04:17 PM
Mizuho Maintains Outperform on Terns Pharma, Raises Price Target to $33
📈 PositiveBenzinga•Nov 13, 2025, 01:30 PM
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $28
📈 PositiveBenzinga•Nov 11, 2025, 03:34 PM•Also:
Terns Pharma Q3 EPS $(0.27) Beats $(0.30) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:43 PM
Frequently Asked Questions about TERN
What is TERN's current stock price?
Terns Pharmaceuticals, Inc. (TERN) is currently trading at $39.90 per share. The stock has moved +0.20% today.
What is the analyst price target for TERN?
The average analyst price target for TERN is $34.83, based on 1 analyst.
What sector is Terns Pharmaceuticals, Inc. in?
Terns Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TERN's market cap?
Terns Pharmaceuticals, Inc. has a market capitalization of $3.59 billion, making it a mid-cap company.
Does TERN pay dividends?
No, Terns Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to TERN for comparison